BioXcel Therapeutics shares are trading lower after the company announced the FDA extended the PDUFA date for its review of the NDA of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II.

by | Dec 1, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.